Workflow
海正药业:核心产品发力 上半年扣非净利润同比增长23.92%

Core Insights - The company reported a revenue of 5.25 billion yuan and a net profit attributable to shareholders of 299 million yuan for the first half of 2025, with a year-on-year growth of 23.92% in net profit [1] - The company implemented a series of reforms including structural optimization and brand enhancement, leading to steady business growth and improved operational performance [1] Financial Performance - The operating cash flow net amount reached 1.211 billion yuan, reflecting a significant year-on-year increase of 54.98% [1] - The sales of core products such as "Saismei" and "Meiman" contributed positively to the revenue growth of the formulation segment [1] Business Segments - The pet medicine business experienced remarkable growth, exceeding 60%, with e-commerce sales surpassing 100 million yuan [1] - The company celebrated the 10th anniversary of its domestic deworming drug "Hailiemiao," which has sold over 45 million tablets [1] R&D and Innovation - The company adopted a combination of self-research and collaboration for innovative drug development, with its self-developed small molecule innovative drug HS387 entering clinical development [2] - Strategic partnerships with AI pharmaceutical companies aim to enhance drug development capabilities, focusing on cutting-edge technology platforms [2] Future Outlook - The company plans to continue leveraging synthetic biology and AI-driven drug development to enhance innovation and global strategy [2] - The establishment of a subsidiary focused on synthetic biology marks a significant step into the high-end synthetic biology industry [2]